PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 6189542-5 1983 The effect was blocked stereoselectively by 1 muM propranolol, suggesting that it occurred through an interaction with lung beta-adrenoceptors. Propranolol 50-61 latexin Homo sapiens 46-49 6127588-4 1982 Alpha-2 adrenergic activation, achieved with 10 muM epinephrine and 30 muM propranolol, significantly inhibited forskolin-stimulated cyclic AMP accumulation and glycerol release, shifting the dose-response curves to the right. Propranolol 75-86 latexin Homo sapiens 71-74 31609806-10 2019 We also found a 100 muM concentration of propranolol cutoff point. Propranolol 41-52 latexin Homo sapiens 20-23 318874-4 1977 At concentrations similar to those achieved in vivo (0.1-1 muM), propranolol raised the thresholds for aggregation of some normal paltelets by adenosine diphosphate (ADP). Propranolol 65-76 latexin Homo sapiens 59-62 318874-5 1977 At higher concentrations (10-50 muM), propranolol abolished the second wave of platelet aggregation induced by ADP and epinephrine, and inhibited aggregation induced by collagen, thrombin, and the ionophore A23187. Propranolol 38-49 latexin Homo sapiens 32-35 932031-6 1976 In contrast, 1.0 muM propranolol essentially completely inhibited the 8-fold stimulation of 1.0 muM epinephrine but had no effect on either basal or adenosine-stimulated activity. Propranolol 21-32 latexin Homo sapiens 17-20 932031-6 1976 In contrast, 1.0 muM propranolol essentially completely inhibited the 8-fold stimulation of 1.0 muM epinephrine but had no effect on either basal or adenosine-stimulated activity. Propranolol 21-32 latexin Homo sapiens 96-99 31222761-3 2019 Short-term (acute) application of the beta-AR antagonist propranolol (25 muM) led to reduction of peak current and quickening of current inactivation (the latter occurred only in 5% fetal bovine serum). Propranolol 57-68 latexin Homo sapiens 73-76 31222761-4 2019 Long-term (48 hr) incubation with propranolol (25 muM) resulted in several changes in VGSC characteristics: shifts in (a) current-voltage relationship and (b) steady-state inactivation, both to more negative potentials and (c) the slowing of recovery from inactivation. Propranolol 34-45 latexin Homo sapiens 50-53 31222761-7 2019 Propranolol (2.5 and 25 muM) and ranolazine (5 muM), and their combination inhibited lateral motility. Propranolol 0-11 latexin Homo sapiens 24-27 31222761-8 2019 Also, propranolol (25 muM) and ranolazine (5 muM), and their combination inhibited invasion. Propranolol 6-17 latexin Homo sapiens 22-25 31609806-12 2019 However, propranolol resulted in a sharp and significant variation in cell morphology and survival rates at high concentrations (100, 200, and 400 muM). Propranolol 9-20 latexin Homo sapiens 147-150 31609806-15 2019 Furthermore, the expressions of phosphorylated AKT and peroxisome proliferator-activated receptor gamma (PPARgamma) were increased with a 100 muM concentration of propranolol in HemSC culture. Propranolol 163-174 latexin Homo sapiens 142-145 30180543-2 2018 Nevertheless, while TAML/H2O2 rapidly degrades the drug propranolol, a micropollutant (MP) of broad concern, propranolol is shown to inhibit its own destruction under concentration conditions amenable to kinetics studies ([propranolol] = 50 muM). Propranolol 109-120 latexin Homo sapiens 241-244 30180543-2 2018 Nevertheless, while TAML/H2O2 rapidly degrades the drug propranolol, a micropollutant (MP) of broad concern, propranolol is shown to inhibit its own destruction under concentration conditions amenable to kinetics studies ([propranolol] = 50 muM). Propranolol 109-120 latexin Homo sapiens 241-244 30180543-8 2018 However, based on the measured kI and calculated equilibrium constant K for propranolol-TAML binding, it is possible to project the impact on kI of reducing [propranolol] from 50 muM to the ultradilute regime typical of MP contaminated waters (<=2 ppb, <=7 nM for propranolol) where inhibition nearly vanishes. Propranolol 76-87 latexin Homo sapiens 179-182 30180543-8 2018 However, based on the measured kI and calculated equilibrium constant K for propranolol-TAML binding, it is possible to project the impact on kI of reducing [propranolol] from 50 muM to the ultradilute regime typical of MP contaminated waters (<=2 ppb, <=7 nM for propranolol) where inhibition nearly vanishes. Propranolol 158-169 latexin Homo sapiens 179-182 30180543-8 2018 However, based on the measured kI and calculated equilibrium constant K for propranolol-TAML binding, it is possible to project the impact on kI of reducing [propranolol] from 50 muM to the ultradilute regime typical of MP contaminated waters (<=2 ppb, <=7 nM for propranolol) where inhibition nearly vanishes. Propranolol 158-169 latexin Homo sapiens 179-182 30180543-9 2018 Projecting from 50 muM to higher concentrations, propranolol completely inhibits its own oxidation before reaching mM concentrations. Propranolol 49-60 latexin Homo sapiens 19-22 25120757-9 2014 Propranolol at 100-150 muM inhibited proliferation of hemSCs, not did 50 muM. Propranolol 0-11 latexin Homo sapiens 23-26 22250754-7 2012 The bound concentration of propranolol enantiomers in the presence of AGP was found to be greater for (S)-propranolol than (R)-propranolol for solutions containing constant concentrations of AGP (50 muM). Propranolol 27-38 latexin Homo sapiens 199-202 22006582-3 2011 In vitro proliferation assay showed that propranolol (from 50-100 muM) induces dose-dependent anti-proliferative effects in a panel of 9 human cancer and "normal" cell lines. Propranolol 41-52 latexin Homo sapiens 66-69 22006582-4 2011 Matrigel assays revealed that propranolol displays potent anti-angiogenic properties at non-toxic concentrations (less than 50 muM) but exert no vascular-disrupting activity. Propranolol 30-41 latexin Homo sapiens 127-130 22006582-7 2011 Furthermore, Matrigel assays indicated that low concentrations of propranolol (10 - 50 muM) potentiated the anti-angiogenic effects of 5-FU and paclitaxel. Propranolol 66-77 latexin Homo sapiens 87-90 23433451-5 2013 Propranolol significantly reversed the inhibitory effect of 100 mum tramadol on KCl-induced myometrial contractility but not that of 300 mum tramadol. Propranolol 0-11 latexin Homo sapiens 64-67 20870013-5 2010 This effect is prevented by the beta-adrenergic receptor antagonist propranolol (2 muM). Propranolol 68-79 latexin Homo sapiens 83-86 21124749-8 2010 Propranolol inhibition of IkappaB phosphorylation was shown to occur with optimal efficacy at 30 muM. Propranolol 0-11 latexin Homo sapiens 97-100 21124749-9 2010 Although propranolol, at up to 100 muM, did not affect cell viability, it potentiated PMA- mediated signaling that ultimately led to diminished phosphorylation of Akt. Propranolol 9-20 latexin Homo sapiens 35-38